33810356|t|In Vitro Assessment of the Antiviral Activity of Ketotifen, Indomethacin and Naproxen, Alone and in Combination, against SARS-CoV-2.
33810356|a|The 2019 coronavirus infectious disease (COVID-19) is caused by infection with the new severe acute respiratory syndrome coronavirus (SARS-CoV-2). Currently, the treatment options for COVID-19 are limited. The purpose of the experiments presented here was to investigate the effectiveness of ketotifen, naproxen and indomethacin, alone or in combination, in reducing SARS-CoV-2 replication. In addition, the cytotoxicity of the drugs was evaluated. The findings showed that the combination of ketotifen with indomethacin (SJP-002C) or naproxen both reduce viral yield. Compared to ketotifen alone (60% inhibition at EC50), an increase in percentage inhibition of SARS-CoV-2 to 79%, 83% and 93% was found when co-administered with 25, 50 and 100 muM indomethacin, respectively. Compared to ketotifen alone, an increase in percentage inhibition of SARS-CoV-2 to 68%, 68% and 92% was found when co-administered with 25, 50 and 100 muM naproxen, respectively. For both drug combinations the observations suggest an additive or synergistic effect, compared to administering the drugs alone. No cytotoxic effects were observed for the administered dosages of ketotifen, naproxen, and indomethacin. Further research is warranted to investigate the efficacy of the combination of ketotifen with indomethacin (SJP-002C) or naproxen in the treatment of SARS-CoV-2 infection in humans.
33810356	49	58	Ketotifen	Chemical	MESH:D007665
33810356	60	72	Indomethacin	Chemical	MESH:D007213
33810356	77	85	Naproxen	Chemical	MESH:D009288
33810356	121	131	SARS-CoV-2	Disease	MESH:D000086382
33810356	137	172	2019 coronavirus infectious disease	Disease	MESH:D000086382
33810356	174	182	COVID-19	Disease	MESH:D000086382
33810356	197	206	infection	Disease	MESH:D007239
33810356	216	265	new severe acute respiratory syndrome coronavirus	Disease	MESH:D000086382
33810356	267	277	SARS-CoV-2	Species	2697049
33810356	317	325	COVID-19	Disease	MESH:D000086382
33810356	425	434	ketotifen	Chemical	MESH:D007665
33810356	436	444	naproxen	Chemical	MESH:D009288
33810356	449	461	indomethacin	Chemical	MESH:D007213
33810356	500	510	SARS-CoV-2	Species	2697049
33810356	541	553	cytotoxicity	Disease	MESH:D064420
33810356	626	635	ketotifen	Chemical	MESH:D007665
33810356	641	653	indomethacin	Chemical	MESH:D007213
33810356	655	663	SJP-002C	Chemical	-
33810356	668	676	naproxen	Chemical	MESH:D009288
33810356	714	723	ketotifen	Chemical	MESH:D007665
33810356	796	806	SARS-CoV-2	Species	2697049
33810356	882	894	indomethacin	Chemical	MESH:D007213
33810356	922	931	ketotifen	Chemical	MESH:D007665
33810356	979	989	SARS-CoV-2	Species	2697049
33810356	1065	1073	naproxen	Chemical	MESH:D009288
33810356	1222	1231	cytotoxic	Disease	MESH:D064420
33810356	1286	1295	ketotifen	Chemical	MESH:D007665
33810356	1297	1305	naproxen	Chemical	MESH:D009288
33810356	1311	1323	indomethacin	Chemical	MESH:D007213
33810356	1405	1414	ketotifen	Chemical	MESH:D007665
33810356	1420	1432	indomethacin	Chemical	MESH:D007213
33810356	1434	1442	SJP-002C	Chemical	-
33810356	1447	1455	naproxen	Chemical	MESH:D009288
33810356	1476	1496	SARS-CoV-2 infection	Disease	MESH:D000086382
33810356	1500	1506	humans	Species	9606
33810356	Negative_Correlation	MESH:D007665	MESH:D000086382
33810356	Cotreatment	MESH:D007213	MESH:D007665
33810356	Cotreatment	MESH:D007665	MESH:D009288
33810356	Negative_Correlation	MESH:D009288	MESH:D000086382
33810356	Negative_Correlation	MESH:D007213	MESH:D000086382

